DA Davidson & Co lowers its rating on Ceradyne CRDN to Neutral from Buy and cuts its price target by $5 to $36 on weak solar business and lower armor margins that weigh on outlook.
DA Davidson & Co comments, "While revenues from the solar crucible business are expected to be ~$72 million in CY11, this business is expected to decline to ~$44 million in CY12. While weakness in the solar business is not new news, we were modeling higher year-over-year solar revenues in CY12. ...Management also noted some delays in body armor shipments that could impact Q4, but we expect the recently announced (in September 2011) $127 million sustainment order for Enhanced Small Arms Protective Inserts (ESAPI) to provide some revenue stability in 2012. However, given the ASP erosion on
the armor front, we expect some margin degradation in the armor business in 2012."
CRDN closed at $31.41 a share on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in